SCHEMBL10286296

SCHEMBL10286296

C#CCOc1cc(C)nc2c1CCCCC2O

nearest known ligand 0.34

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
UGT2B17 O75795 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.32
ACHE P22303 1/20 0.32
MAOB P27338 4/20 0.31
MAOA P21397 3/20 0.31
PGK1 P00558 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10286036 0.96 UGT2B17 (0.38) UGT2B17L3MBTL1ACHEMAOBMAOA
SCHEMBL10286314 0.85 RXFP1 (0.34) UGT2B17ACHE
SCHEMBL10286358 0.82 MCHR1 (0.34) UGT2B17ACHE
SCHEMBL10286178 0.81 UGT2B17 (0.38) UGT2B17ACHE
SCHEMBL10286291 0.81 MAPT (0.34) UGT2B17ACHE
SCHEMBL10286319 0.80 MAPT (0.36) UGT2B17ACHEMAOA
SCHEMBL10286196 0.79 MAOB (0.32) MAOBMAOAPGK1
SCHEMBL10286324 0.78 UGT2B17 (0.36) UGT2B17ACHE
SCHEMBL10286182 0.77 UGT2B17 (0.35) UGT2B17ACHE
SCHEMBL10287375 0.77 CNR2 (0.35) UGT2B17ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130102631-A1 NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES SYNGENTA CROP PROTECTION LLC (US) 2013-04-25 US disclosed
US-20130102631-A1 NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES SYNGENTA CROP PROTECTION LLC (US) 2013-04-25 US disclosed
WO-2012001040-A1 NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102631-A1 NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES MSR1, DDT, MPO UGT2B17 1446/4885L3MBTL1 850/4885ACHE 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.